Evidence map›Paper›PMID 42611221›Full record

ArticleACS nano2026

Analysis of Pharmacokinetic-Pharmacodynamic Relationships of Nanoparticles against Tumors.

Kun Mi, Qiran Chen, Long Yuan, Chunla He, Nancy A Monteiro-Riviere, Jim E Riviere, Zhoumeng Lin

Abstract read
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kun MiDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida32611, United States.
Qiran ChenDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida32611, United States.
Long YuanDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida32611, United States.
Chunla HeDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida32611, United States.
Nancy A Monteiro-RiviereNanotechnology Innovation Center of Kansas State, Kansas State University, Manhattan, Kansas66506, United States.
Jim E RiviereCenter for Chemical Toxicology Research and Pharmacokinetics, North Carolina State University, Raleigh, North Carolina27606, United States.
Zhoumeng LinDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida32611, United States.ORCID 0000-0002-8731-8366

Funding

Development of a web-based predictive model of nanoparticle delivery to tumors by integrating physiologically-based pharmacokinetic modeling with artificial intelligenceR01EB031022 · NIBIB · UNIVERSITY OF FLORIDA · PI Zhoumeng Lin · 2021 to 2026
$2.2M
NIBIB NIH HHS R01 EB031022NIBIB NIH HHS R01EB031022
6 · The paper itself

Abstract

Nanoparticle (NP)-based drug delivery systems hold great promise for cancer treatment. However, designing efficient NP formulations for clinical usage remains a challenge. This study created a "Nano-PKPD Database" by curating pharmacokinetic (PK) data on NP tumor delivery and tissue biodistribution, as well as pharmacodynamic (PD) data on tumor volume changes in tumor-bearing mice. Various machine learning (ML) models were developed to explore the PK-PD relationship and predict antitumor efficacy based on NP physicochemical properties, experimental strategies, and PK metrics. The current database contains 611 data sets from 345 papers on NP time-dependent concentrations in tumors and major organs. The median delivery efficiency was 0.70 percentage of injected dose (%ID) in tumors, 0.17%ID (heart), 10.72%ID (liver), 0.59%ID (spleen), 0.33%ID (lung), and 0.96%ID (kidney). In addition, 833 data sets from 340 papers on time-dependent tumor volume changes were collected, where the median tumor growth inhibition was 63.12%. A total of 18 ML models were developed, where tree-based models achieved the best discriminative performance. The use of assistive technology, zeta potential, and targeting strategy were the top 3 features related to antitumor efficacy. This study reports an open-access database and multiple ML models for PK-PD investigation, facilitating nanomedicine design and accelerating clinical translation.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsAnimalsDatabases, FactualHumansMachine LearningMiceTissue DistributionAntineoplastic Agentsartificial intelligencemachine learningnanoparticlepharmacodynamicpharmacokinetictumor

Identifiers

PMID42611221
PMCPMC13488496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.